Caroline Germa was named chief medical officer at Ikena Oncology Inc.
Positive high-level results from the EMERALD-1 phase III trial showed Imfinzi (durvalumab) in combination with transarterial chemoembolization, or TACE, and bevacizumab demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of progression-free survival versus TACE alone in patients with hepatocellular carcinoma eligible for embolization. The trial continues to follow the secondary endpoint of overall survival.
Positive high-level results from the FLAURA2 phase III trial showed Tagrisso (osimertinib) in combination with chemotherapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared to Tagrisso alone for patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer.
Thermo Fisher Scientific and AstraZeneca formed a global, multiyear agreement to develop a solid tissue and blood-based companion diagnostic test for Tagrisso (osimertinib).
Ibex Medical Analytics entered into an agreement with AstraZeneca and Daiichi Sankyo for the development, clinical validation, and early adoption of an AI-powered product to aid pathologists with an accurate and reproducible assessment of HER2 immunohistochemistry scoring in breast cancer patients.
C2i Genomics extended its collaboration with AstraZeneca to evaluate the potential of whole-genome minimal residual disease testing across solid cancers, with the goal of enhancing oncology treatment, supporting clinical trial recruitment, and monitoring.
Detailed results from the CAPItello-291 phase III trial showed AstraZeneca’s capivasertib in combination with Faslodex (fulvestrant) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival versus placebo plus Faslodex in patients with hormone receptor-positive, human epidermal growth factor receptor 2-low or negative, locally advanced or metastatic breast cancer, following recurrence or progression on, or after, endocrine therapy (with or without a CDK4/6 inhibitor).
Neogene Therapeutics Inc., a global clinical-stage biotechnology company pioneering the discovery, development, and manufacturing of next-generation T cell receptor therapies, will be acquired by AstraZeneca.
The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion recommending approval of Lynparza (olaparib) in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with metastatic castration-resistant prostate cancer in whom chemotherapy is not clinically indicated.
FDA has approved Imjudo (tremelimumab) in combination with Imfinzi (durvalumab) and platinum-based chemotherapy for adult patients with metastatic non-small cell lung cancer with no sensitizing EGFR mutation or anaplastic lymphoma kinase genomic tumor aberrations.
